Evidence map›Paper›PMID 25892894›Full record

ArticleWorld journal of gastroenterology2015

Secondary acute promyelocytic leukemia following chemotherapy for gastric cancer: a case report.

Ying-Cheng Zhang, Yu-Qi Zhou, Bing Yan, Jun Shi, Li-Juan Xiu, Yu-Wei Sun, Xuan Liu, Zhi-Feng Qin, Pin-Kang Wei, Yong-Jin Li

Open access · hybridAbstract readCase Reports
In one paragraph

Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Azacitidine-induced hyperglycaemia.BMJ case reports · 2019
    Article
  5. P190Chinese medical journal · 2017
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ying-Cheng ZhangYing-Cheng Zhang, Yu-Qi Zhou, Bing Yan, Jun Shi, Li-Juan Xiu, Yu-Wei Sun, Xuan Liu, Zhi-Feng Qin, Pin-Kang Wei, Yong-Jin Li, Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Yu-Qi ZhouYing-Cheng Zhang, Yu-Qi Zhou, Bing Yan, Jun Shi, Li-Juan Xiu, Yu-Wei Sun, Xuan Liu, Zhi-Feng Qin, Pin-Kang Wei, Yong-Jin Li, Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Bing YanYing-Cheng Zhang, Yu-Qi Zhou, Bing Yan, Jun Shi, Li-Juan Xiu, Yu-Wei Sun, Xuan Liu, Zhi-Feng Qin, Pin-Kang Wei, Yong-Jin Li, Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Jun ShiYing-Cheng Zhang, Yu-Qi Zhou, Bing Yan, Jun Shi, Li-Juan Xiu, Yu-Wei Sun, Xuan Liu, Zhi-Feng Qin, Pin-Kang Wei, Yong-Jin Li, Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Li-Juan XiuYing-Cheng Zhang, Yu-Qi Zhou, Bing Yan, Jun Shi, Li-Juan Xiu, Yu-Wei Sun, Xuan Liu, Zhi-Feng Qin, Pin-Kang Wei, Yong-Jin Li, Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Yu-Wei SunYing-Cheng Zhang, Yu-Qi Zhou, Bing Yan, Jun Shi, Li-Juan Xiu, Yu-Wei Sun, Xuan Liu, Zhi-Feng Qin, Pin-Kang Wei, Yong-Jin Li, Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Xuan LiuYing-Cheng Zhang, Yu-Qi Zhou, Bing Yan, Jun Shi, Li-Juan Xiu, Yu-Wei Sun, Xuan Liu, Zhi-Feng Qin, Pin-Kang Wei, Yong-Jin Li, Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Zhi-Feng QinYing-Cheng Zhang, Yu-Qi Zhou, Bing Yan, Jun Shi, Li-Juan Xiu, Yu-Wei Sun, Xuan Liu, Zhi-Feng Qin, Pin-Kang Wei, Yong-Jin Li, Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Pin-Kang WeiYing-Cheng Zhang, Yu-Qi Zhou, Bing Yan, Jun Shi, Li-Juan Xiu, Yu-Wei Sun, Xuan Liu, Zhi-Feng Qin, Pin-Kang Wei, Yong-Jin Li, Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Yong-Jin LiYing-Cheng Zhang, Yu-Qi Zhou, Bing Yan, Jun Shi, Li-Juan Xiu, Yu-Wei Sun, Xuan Liu, Zhi-Feng Qin, Pin-Kang Wei, Yong-Jin Li, Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
Hainan Branch of People's Liberation Army General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy-related acute myeloid leukemia (t-AML) refers to a heterogeneous group of myeloid neoplasms that develop in patients following extensive exposure to either cytotoxic agents or radiation. The development of t-AML has been reported following treatment of cancers ranging from hematological malignancies to solid tumors; however, to our knowledge, t-AML has never been reported following treatment of gastric cancer. In this study, we report the development of t-acute promyelocytic leukemia in a cT4N1M0 gastric cancer patient after an approximate 44 mo latency period following treatment with 4 cycles of oxaliplatin (OXP) (85 mg/m(2) on day 1) plus capecitabine (1250 mg/m(2) orally twice daily on days 1-14) in combination with recombinant human granulocyte-colony stimulating factor treatment. Karyotype analysis of the patient revealed 46,XY,t(15;17)(q22;q21)[15]/46,idem,-9,+add(9)(p22)[2]/46,XY[3], which, according to previous studies, includes some "favorable" genetic abnormalities. The patient was then treated with all-trans retinoic acid (ATRA, 25 mg/m(2)/d) plus arsenic trioxide (ATO, 10 mg/d) and attained complete remission. Our case illuminated the role of certain cytotoxic agents in the induction of t-AML following gastric cancer treatment. We recommend instituting a mandatory additional evaluation for patients undergoing these therapies in the future.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsyCapecitabineGranulocyte Colony-Stimulating FactorHumansKaryotypingLeukemia, Promyelocytic, AcuteMaleOrganoplatinum CompoundsOxaliplatinPredictive Value of TestsRemission InductionRisk FactorsStomach NeoplasmsBiomarkers, TumorCapecitabineGranulocyte Colony-Stimulating FactorOrganoplatinum CompoundsOxaliplatinAcute promyelocytic leukemiaCapecitabineChemotherapyGastric cancerOxaliplatin

Identifiers

PMID25892894
PMCPMC4394105
OpenAlexW2329711020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.